Aquestive Therapeutics to Join Upcoming Investor Conferences
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a prominent pharmaceutical company dedicated to enhancing patient outcomes through innovative science and delivery technologies, is excited to announce its involvement in two significant investor conferences taking place in September.
Conference Details
The management team from Aquestive Therapeutics will be presenting at the following events:
- H.C. Wainwright 26th Annual Global Investor Conference: Scheduled for 8:30 am ET on the designated date, this presentation will also feature opportunities for one-on-one meetings with investors.
- Lake Street BIG8 Conference: This event will provide a valuable platform for management to connect with investors through meetings.
Webcast Access for Investors
For those unable to attend in person, a live webcast of the H.C. Wainwright presentation will be available on the "Events and Presentation" page in the Investors section of the company’s website. Additionally, a replay of the presentation will be accessible for 30 days after the live event, allowing interested individuals to catch up on the insights shared.
About Aquestive Therapeutics
Aquestive is at the leading edge of pharmaceutical innovation, concentrating on the creation of orally administered products that effectively deliver complex molecules. This strategy offers new alternatives to traditional, often inconvenient, invasive therapies.
Commercial Achievements
The company has successfully launched five products, which are distributed worldwide through licensing agreements. As the sole manufacturer of these products, Aquestive plays a crucial role in the supply chain.
Collaborations and Innovation
Aquestive collaborates with other pharmaceutical companies to introduce new molecules to the market. By leveraging proprietary technologies such as the well-known PharmFilm® and its extensive drug development expertise, the company continuously strives to expand and improve patient treatment options.
Future Product Pipeline
Aquestive is progressing with a late-stage product candidate aimed at treating severe allergic reactions, including anaphylaxis. Furthermore, the company is developing an early-stage prodrug topical gel candidate for various dermatological conditions, showcasing its commitment to broadening treatment options across diverse health challenges.
Investor Contact Information
For more details about Aquestive Therapeutics or its upcoming presentations, interested individuals can reach out to their investor relations team:
ICR Westwicke
Stephanie Carrington
Email: stephanie.carrington@westwicke.com
Phone: 646-277-1282
Frequently Asked Questions
What is the purpose of the upcoming investor conferences?
The conferences provide an opportunity for Aquestive Therapeutics to showcase their latest innovations and engage with investors regarding company developments and future plans.
Who is invited to attend the presentations?
Investors, analysts, and other stakeholders interested in learning more about Aquestive Therapeutics are warmly invited to attend the presentations and meetings.
Will there be a recording of the presentations available?
Yes, webcasts of the presentations will be accessible on the company’s website, with replays available for 30 days following the events.
What type of products is Aquestive developing?
Aquestive is focused on creating innovative orally administered medications that offer alternatives to traditional therapies, including products for allergic reactions and dermatological conditions.
How can investors contact Aquestive for further inquiries?
Investors can reach the investor relations team via email at stephanie.carrington@westwicke.com or by calling 646-277-1282.
